( nger patients and in menand women wit...)New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension,Health

Long-term safety and efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension T Kushiro, H Itakura, Y Abo, H Gotou, S Terao, DL Keefe; Poster P-406

* Long-term therapy with aliskiren alone or in combination with a diuretic and/or calcium channel blocker in Japanese patients with hypertension is well tolerated and provides effective blood pressure reductions that are maintained over 52 weeks of treatment.

Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension AH Gradman, RE Kolloch, M Meyers, J Cai, J Zhang; Poster P-384

* Aliskiren, as monotherapy and in combination with hydrochlorothiazide, provides an effective and well-tolerated long-term treatment for hypertension. Furthermore, the high-dose combination of aliskiren/hydrochlorothiazide (300 mg/25 mg) shows good tolerability and durable blood pressure-lowering efficacy over 12 months of treatment.

Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension RE Schmieder, T Philipp, J Guerediaga, M Gorostidi, B Smith, N Weissbach, A Krebs-Brown, H van Ingen; Poster P-436

* Long-term aliskiren-based therapy was well tolerated and provided significantly greater blood pressure reductions than hydrochlorothiazide-based therapy in patients with mild-to-moderate hypertension. * Aliskiren 300 mg monotherapy was superior to hydrochlorothiazide 25 mg monotherapy in lowering blood pressure.

About SPP100 (aliskiren, Tekturna/Rasilez[9]) SPP100 (aliskiren, Tekturna/Rasilez) is the first-in-class oral direct renin inhibitor. The development of SPP100 is the result of over 20 years of research on renin. Renin is the key enzyme at the top of the Renin Angiotensin System (
'"/>